Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.4420
+0.0180 (4.25%)
At close: Oct 9, 2026, 4:00 PM EDT
0.4560
+0.0140 (3.17%)
After-hours: Oct 9, 2026, 7:49 PM EDT
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Moleculin Biotech the 38,780th largest employer in the world and 5,638th in the United States.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,913,235
Market Cap
8.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - | 17 | 0 |
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| Longeveron | 38 |
| Bolt Biotherapeutics | 23 |
| Lisata Therapeutics | 21 |
| CalciMedica | 15 |
| FibroBiologics | 15 |
| Soligenix | 14 |
| Azitra | 13 |
MBRX News
- 4 days ago - Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit - GlobeNewsWire
- 12 days ago - Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial - TheFly
- 12 days ago - Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout - GlobeNewsWire
- 13 days ago - Moleculin Biotech announces publication of analysis of Annamycin in Frontiers - TheFly
- 13 days ago - Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine - GlobeNewsWire
- 16 days ago - Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR - GlobeNewsWire
- 18 days ago - Moleculin Biotech secures Mexican patent protecting Annamycin through 2040 - TheFly
- 18 days ago - Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 - GlobeNewsWire